A U.S. Dept. of Justice probe into Medtronic Inc.’s (NYSE:MDT) marketing practices for its Infuse bone growth product line is growing, according to a report in the New York Times.
The Old Grey Lady reports that federal prosecutors are grilling physicians in connection with the investigation and have sought records from the U.S. Army, which participated in a later-retracted study investigating the use of Infuse in wounded combat veterans.